CELL AND GENE THERAPY
CSL Plasma | March 11, 2022
CSL Plasma, a division of global biotherapeutics pioneer CSL Behring, announced the Rika Plasma Donation System created by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado, has received regulatory approval.
The new plasmapheresis system is expected to provide technologies to support a safe, efficient, and better experience for plasma donors and an improved experience for CSL Plasma personnel, according to Terumo Blood and Cell Technologies.
Additional characteristics of the new Rika system, according to CSL Plasma, will allow for the collection of more plasma in less time, hence improving quality and safety and, in turn, better serving patients who rely on plasma-based therapies. These advantages include:
On average, Rika completes one plasma collection in 35 minutes or less: Compared to previous average CSL Plasma donation timings, this might mean a nearly 30% reduction in donor donation time.
It assures that no more than 200 milliliters of blood are ever removed from the donor's body. This is believed to make the donor more comfortable during the donation process and lessen the risk of red cell loss deferral.
It has a sophisticated user interface that helps CSL Plasma front-line personnel operate the equipment.
This milestone helps bring to life how we demonstrate innovation, collaboration, and patient-focus, part of the CSL Values that underpin our commitment to manufacturing and delivering life-saving and life-extending medicines around the world, We continue to evolve as a leading biotechnology company, investing in our core plasma business. Continued innovation that benefits our employees and plasma donors speak to how we are driven by our promise to save and improve lives around the world."
CSL Chief Operating Officer Paul McKenzie.
CSL Plasma will begin installing the new technology at locations in the Denver, Colorado, area in the following months.
There is a critical and ongoing need for human plasma to produce life-saving medicines for people with serious and rare diseases, CSL Plasma's decision to work with Terumo Blood and Cell Technologies is consistent with our business goals to improve the donor and employee experience through innovation and remain the plasma donation center of choice. We look forward to rolling out this new technology."
CSL Plasma General Manager Michelle Meyer.
Slate Bio | January 20, 2021
Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's lead candidate, is a first in class drug that initiates constant abatement in animal models of autoimmune and inflammatory diseases.
Slate's IL233 is a bifunctional IL-2 combination cytokine that increases Regulatory T cells (Tregs) and tissue resident Tregs for autoimmune and provocative infections. IL233 joins the de-gambling certainty of IL-2 and the collaboration and toughness of IL-33. IL233 goes about as a pharmacological kick off to revive the body's inherent pathways to stop inflammation, end mal-adaptive repair and promote regeneration of damaged tissues to restore homeostasis.
Sartorius Stedim Biotech | December 10, 2020
Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical business, today procured U.S.- based filtration master WaterSep BioSeparations LLC. WaterSep BioSeparations develops, makes and markets empty fiber layer gadgets and pre-cleaned congregations for upstream and downstream biopharmaceutical applications. The exclusive organization situated in Marlborough, Massachusetts, USA, employs around 15 individuals and is required to procure income of approximately 2.5 million U.S. dollars in 2020 at solid development rates and a generous twofold digit EBITDA edge. The gatherings conceded to a price tag of roughly 27 million U.S. dollars in addition to a procure out segment of up to 9 million U.S. dollars, contingent upon the accomplishment of characterized deals revenue growth by 2023.
This official statement contains forward-looking articulations about the future development of the Sartorius Stedim Biotech Group. Forward-looking proclamations are liable to known and obscure dangers, vulnerabilities and different elements that could make real outcomes vary substantially from those communicated or suggested by such explanations. Sartorius Stedim Biotech accepts no risk for refreshing such articulations considering new data or future occasions. This is an interpretation of the first French-language public statement. Sartorius Stedim Biotech will not assume any risk for the accuracy of this translation. The first French official statement is the legally binding version.